Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 2/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine Elaidate SCHEMBL582035 | 1.00 | PDE4D (0.56) | PDE4DPDE3ASLC29A1POLA1LPAR1 | |
| Gemcitabine Elaidate SCHEMBL14460099 | 1.00 | PDE4D (0.56) | PDE4DPDE3ASLC29A1POLA1LPAR1 | |
| Gemcitabine Elaidate SCHEMBL582036 | 1.00 | PDE4D (0.56) | PDE4DPDE3ASLC29A1POLA1LPAR1 | |
| SCHEMBL15197943 | 0.95 | PDE4D (0.62) | PDE4DPDE3ASLC29A1POLA1LPAR1 | |
| SCHEMBL21849051 | 0.92 | PDE4D (0.63) | PDE4DPDE3ASLC29A1POLA1L3MBTL1 | |
| SCHEMBL22760865 | 0.90 | PDE4D (0.56) | PDE4DPDE3ASLC29A1POLA1L3MBTL1 | |
| SCHEMBL4938679 | 0.90 | PDE3A (0.60) | PDE4DPDE3ASLC29A1POLA1L3MBTL1 | |
| SCHEMBL5188355 | 0.90 | PDE3A (0.60) | PDE4DPDE3ASLC29A1POLA1L3MBTL1 | |
| SCHEMBL4940086 | 0.90 | PDE3A (0.60) | PDE4DPDE3ASLC29A1POLA1L3MBTL1 | |
| SCHEMBL4941183 | 0.90 | PDE3A (0.60) | PDE4DPDE3ASLC29A1POLA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | claimed |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | claimed |
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2022-10-20 | — | — | US | claimed |
| CN-114430059-B | Fuel cell | 现代自动车株式会社 | 2025-05-09 | — | — | CN | disclosed |
| CN-119947697-A | Mild detergent compositions with biodegradable thickeners and enhanced microbiota impact | 联合利华知识产权控股有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119677491-A | Stable detergent compositions with unsaturated zwitterionic surfactants | 联合利华知识产权控股有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114640418-B | Time starting moment pure transparent transmission method for optical wavelength division multiplexing transmission system | 东莞市宇欣电子科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119384283-A | Compositions and methods for treating cancer using modified SIRNA-GEM agents | 圣诺制药公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20250027086-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCERS USING MODIFIED siRNA-GEM AGENTS | SIRNAOMICS INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20250009730-A1 | IFENPRODIL SALTS AND THERAPEUTIC USES THEREOF | ALGERNON PHARMACEUTICALS INC. (CA) | 2025-01-09 | — | — | US | disclosed |
| US-8329665-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324180-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2416781-A1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | Eisai Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2417146-A1 | (2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER | Eisai Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010118006-A1 | (2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118013-A1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | PDE4D 266/4885PDE3A 86/4885SLC29A1 1797/4885 |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | PDE4D 266/4885PDE3A 86/4885SLC29A1 1797/4885 |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | PDE4D 2388/4885PDE3A 1457/4885SLC29A1 3938/4885 |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | PDE4D 1325/4885PDE3A 340/4885SLC29A1 4541/4885 |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | PDE4D 2388/4885PDE3A 1457/4885SLC29A1 3938/4885 |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | PDE4D 266/4885PDE3A 86/4885SLC29A1 1797/4885 |
| US-20250009730-A1 | IFENPRODIL SALTS AND THERAPEUTIC USES THEREOF | PPARD, PPARA, HPGD | PDE4D 1134/4885PDE3A 326/4885SLC29A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.